DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 937 filers reported holding DANAHER CORPORATION in Q4 2014. The put-call ratio across all filers is 0.82 and the average weighting 0.5%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $32,948,921 | +33.3% | 132,805 | +28.9% | 2.55% | +39.0% |
| Q2 2023 | $24,726,000 | -43.3% | 103,025 | -40.5% | 1.83% | -44.4% |
| Q1 2023 | $43,616,530 | -18.5% | 173,054 | -14.2% | 3.30% | -17.6% |
| Q4 2022 | $53,531,233 | +5.8% | 201,685 | +3.0% | 4.00% | -1.1% |
| Q3 2022 | $50,577,000 | -75.6% | 195,817 | -76.0% | 4.04% | -4.1% |
| Q2 2022 | $207,254,000 | -28.9% | 817,509 | -17.7% | 4.22% | -17.2% |
| Q1 2022 | $291,352,000 | +245.7% | 993,257 | +287.8% | 5.09% | +9.1% |
| Q4 2021 | $84,277,000 | +16.3% | 256,155 | +7.6% | 4.67% | +11.0% |
| Q3 2021 | $72,455,000 | +761.8% | 237,995 | +659.6% | 4.20% | +724.5% |
| Q2 2021 | $8,407,000 | +18.3% | 31,330 | -0.8% | 0.51% | +4.9% |
| Q1 2021 | $7,106,000 | +1.1% | 31,573 | -0.2% | 0.49% | -0.8% |
| Q4 2020 | $7,027,000 | -85.8% | 31,636 | -93.1% | 0.49% | -78.8% |
| Q3 2018 | $49,471,000 | +19.0% | 455,279 | +8.0% | 2.31% | +1.1% |
| Q2 2018 | $41,588,000 | +11.3% | 421,446 | +10.4% | 2.29% | -14.4% |
| Q1 2018 | $37,364,000 | +78.4% | 381,606 | +69.2% | 2.67% | +14.3% |
| Q4 2017 | $20,941,000 | +8.2% | 225,547 | 0.0% | 2.34% | +39.5% |
| Q3 2017 | $19,347,000 | +33.1% | 225,547 | +31.0% | 1.68% | +32.1% |
| Q2 2017 | $14,531,000 | +9.5% | 172,192 | +10.9% | 1.27% | +8.5% |
| Q1 2017 | $13,276,000 | +9.4% | 155,227 | -0.5% | 1.17% | +2.2% |
| Q4 2016 | $12,139,000 | -4.3% | 155,953 | -3.6% | 1.14% | -11.7% |
| Q3 2016 | $12,679,000 | -9.6% | 161,736 | +16.5% | 1.30% | -15.5% |
| Q2 2016 | $14,025,000 | +11.0% | 138,858 | +4.2% | 1.53% | +2.1% |
| Q1 2016 | $12,640,000 | +6.8% | 133,244 | +4.6% | 1.50% | -2.2% |
| Q4 2015 | $11,831,000 | +9.0% | 127,375 | -0.0% | 1.53% | +4.8% |
| Q3 2015 | $10,855,000 | +2.1% | 127,388 | +2.6% | 1.46% | +11.8% |
| Q2 2015 | $10,627,000 | +2.6% | 124,164 | +1.8% | 1.31% | -0.7% |
| Q1 2015 | $10,357,000 | -4.9% | 121,984 | -4.0% | 1.32% | -8.0% |
| Q4 2014 | $10,891,000 | +27.3% | 127,064 | +12.8% | 1.43% | +15.6% |
| Q3 2014 | $8,558,000 | -3.5% | 112,635 | 0.0% | 1.24% | +6.0% |
| Q2 2014 | $8,868,000 | +4.2% | 112,635 | -0.7% | 1.17% | -2.3% |
| Q1 2014 | $8,510,000 | +62.0% | 113,472 | +66.8% | 1.20% | +25.2% |
| Q4 2013 | $5,252,000 | – | 68,037 | – | 0.96% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |